NY1972
1 년 전
I view ICE+PD-L1 as jockey and horse. You need Pd-L1 to upregulate cancer cell necrosis genes, block the IC on M, NK, T. ICE is the jockey that direct and activates the NK, M to the weakened cancer cells to make the kill. Turning the trojan horse into CARNK, CARM without CRISPR, IPSC etc..
jondoeuk
1 년 전
The ESMO abstract
1017O - NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
Background
Neoantigens are tumor-specific antigens derived from somatic mutations and have been shown to elicit antitumor immune responses. The interim results of a phase I study (NCT04625205) testing a personalized, non-engineered, neoantigen-specific T cell product (BNT221) targeting multiple neoantigens are presented.
Methods
Nine patients with checkpoint- and, if applicable, BRAFi-resistant metastatic melanoma were treated with BNT221. Up to sixty immunogenic MHCI- and MHCII-restricted neoantigens were selected using our RECON® bioinformatics platform and used in an ex vivo induction process (NEO-STIM™) to prime, activate and expand memory and de novo T-cell responses from both the CD4+ and the CD8+ T cell compartment, using PBMCs collected via leukapheresis. Two BNT221 doses (≥ 1 × 108 cells to ≤ 1 × 109 cells and >2 × 109 cells to ≤ 1 × 1010 cells) were evaluated in a 3+3 escalation design, with primary (safety and determination of highest tolerable dose), secondary (efficacy, per RESIST 1.1) and exploratory endpoints. Patients were treated with lymphodepleting chemotherapy prior to infusion. Peripheral blood and biopsies were collected for immune monitoring.
Results
BNT221 was well-tolerated. No dose-limiting toxicities were observed, with grade 3-4 toxicities post infusion limited to hematologic toxicities from lymphodepletion. Seven patients showed stable disease as best overall response (12-36+ weeks). Of those, two patients showed tumor reductions at cutaneous and visceral disease sites and reported quality of life improvements. For all patients, drug products were generated with multiple neoantigen specific CD8+ and CD4+ T cell responses, also detected up to 6 weeks post infusion. Evidence of tumor infiltration was observed through TCR sequencing analysis in one patient tested.
Conclusions
In this first in human study, BNT221 as a single infusion therapy demonstrated a tolerable safety profile, product persistence, prolonged stable disease, and tumor regressions in patients with checkpoint inhibitor-resistant metastatic melanoma. Additional study is warranted and BNT221 combination with anti-PD-1 is currently underway.
DewDiligence
2 년 전
CVAC ups_the_ante_in COVID-vaccine patent suits_against PFE/BNTX:
https://www.accesswire.com/viewarticle.aspx?id=767607&lang=en
The market appears to be skeptical of CVAC’s litigation prospects in either Germany or the US. Background info from the above PR: CureVac filed a patent infringement lawsuit in Germany against BioNTech in early June 2022. A first public hearing on this lawsuit will take place on August 15, 2023, before the Regional Court Düsseldorf. A nullity action covering one of the patents at issue (EP1857122B1) was filed by Pfizer/BioNTech in September 2022. A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent.
In the U.S., Pfizer/BioNTech filed its case in late July 2022, asking for confirmation that Comirnaty does not infringe three CureVac patents. These patents are included in the ten U.S. patents of CureVac's counter¬claim: 11,135,312; 11,149,278; 11,286,492; 11,345,920; 10,760,070; 11,241,493; 11,471,525; 11,576,966; 11,596,686 and 11,667,910.
jondoeuk
2 년 전
The company announces an exclusive license and collaboration agreement with OncoC4 on Monday to jointly develop and commercialise the latter's, ONC-392. ONC-392 is an anti-CTLA-4 mAb candidate. Under the partnership, BNTX and OncoC4 will equally share the costs to develop it as monotherapy and in combination with anti-PD-(L)-1 mAbs for multiple solid tumours.
Per the terms, OncoC4 will receive $200M upfront in addition to future payments linked to development, regulatory and commercial milestones, and double-digit tiered royalties.
Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Monksdream
3 주 전
PonkenPlonken
3 주 전
axelvento
1 월 전
BottomBounce
2 년 전
